Previous close | 2.5000 |
Open | 2.5000 |
Bid | 2.0000 |
Ask | 5.6000 |
Strike | 300.00 |
Expiry date | 2024-06-21 |
Day's range | 2.5000 - 2.5000 |
Contract range | N/A |
Volume | |
Open interest | 81 |
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alnylam (ALNY) delivered earnings and revenue surprises of 78.67% and 17.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 02, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.